Abstract
The B-cell lymphoma-2 (BCL-2) family of proteins are essential components in the intrinsic apoptosis pathway. While a primary mechanism for the removal of damaged or unwanted cells, dysregulation of this pathway is observed in many human cancers. Specifically, BCL-2 overexpression has been associated with pro-survival of multiple hematological and solid tumor malignancies. In the clinic, BCL-2 inhibitors have demonstrated impressive efficacy in hematological diseases, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
